Microhelenin C exhibits significant antitumor activity, particularly against certain human cancer cell lines. It functions by interfering with microtubule dynamics, which disrupts cell division and induces apoptosis in rapidly dividing cells. This makes it a candidate for development in oncology therapeutics, especially in cancers showing resistance to conventional microtubule-targeting agents. Additionally, it has shown anti-inflammatory properties in preclinical models, suggesting potential use in treating chronic inflammatory conditions. Research is ongoing to evaluate its efficacy and safety for pharmaceutical applications.